Neglected Tropical Disease Treatment Market Report 2026

The neglected tropical disease treatment market size has grown strongly in recent years. It will grow from $3.57 billion in 2025 to $3.8 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to long-standing disease prevalence in tropical regions, support from global health organizations, expansion of donor-funded treatment programs, availability of generic therapeutics, increased public health awareness initiatives.

The neglected tropical disease treatment market size is expected to see strong growth in the next few years. It will grow to $4.79 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to increasing investments in eradication programs, rising adoption of integrated disease management approaches, expansion of novel antiparasitic drug development, growing public-private partnerships, increasing focus on healthcare access in remote regions. Major trends in the forecast period include increasing deployment of combination drug therapies, rising focus on early disease detection programs, growing use of mass drug administration strategies, expansion of community-based treatment models, enhanced emphasis on treatment accessibility.

The rising prevalence of infectious diseases is expected to drive the growth of the neglected tropical disease treatment market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms, including bacteria, viruses, fungi, or parasites, that can spread directly or indirectly between individuals. The increase in infectious diseases is largely due to growing travel, which facilitates the rapid transmission of pathogens across regions. Neglected tropical disease treatments support the management of infectious diseases by providing targeted therapies that control and reduce disease spread. These treatments enhance public health outcomes, particularly in vulnerable populations, by lowering disease burden and preventing long-term disabilities. For instance, in February 2024, according to the UK Health Security Agency, a UK-based government organization, tuberculosis cases in England increased to 4,850 in 2023, up 10.7% from 4,380 cases in 2022. Therefore, the rising prevalence of infectious diseases is fueling growth in the neglected tropical disease treatment market.

The expansion of healthcare infrastructure is also expected to propel the growth of the neglected tropical disease treatment market. Healthcare infrastructure encompasses the facilities, equipment, systems, and workforce required to deliver effective medical care to a population. Its growth is driven by population increases, as expanding communities necessitate more hospitals, clinics, and medical facilities to meet healthcare demand. Neglected tropical disease treatments benefit healthcare infrastructure by reducing infection spread, creating safer patient environments, and helping hospitals maintain higher hygiene standards. For instance, in 2024, according to the American Hospital Association, a US-based non-profit organization, the United States had 6,120 hospitals, up from 6,093 in 2022. Therefore, the expansion of healthcare infrastructure is supporting growth in the neglected tropical disease treatment market.

Key companies operating in the neglected tropical disease treatment market are focusing on innovative solutions, such as all-oral, field-deployable therapeutics, designed to simplify administration, enhance safety, and increase access in low-resource settings. All-oral therapies for diseases such as human African trypanosomiasis consist of small-molecule drugs taken orally over a short course, improving treatment reach, reducing hospitalization needs, and lowering operational barriers compared with traditional injectable therapies. For example, in December 2023, Sanofi S.A., a France-based multinational pharmaceutical company, launched Fexinidazole Winthrop, an oral treatment developed in collaboration with non-profit organizations. Fexinidazole, a nitro-containing small molecule, replaces older regimens requiring intravenous administration or hospitalization. Its oral formulation, simplified dosing schedule, and favorable safety profile make it suitable for use across both stages of certain forms of sleeping sickness, expanding treatment accessibility in remote areas. Fexinidazole also contrasts with traditional alternatives such as melarsoprol and eflornithine, which are injectable, require complex monitoring, and have higher toxicity and operational challenges.

Major companies operating in the neglected tropical disease treatment market are Pfizer Inc, Johnson And Johnson, Merck And Co Inc, AbbVie Inc, Bayer AG, Novartis AG, Sanofi SA, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc, Eisai Co Ltd, Shionogi And Co Ltd, Dr Reddys Laboratories Ltd, Cipla Ltd, Gilead Sciences Inc, Bristol Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Lupin Limited, Alvogen.

Asia-Pacific was the largest region in the neglected tropical disease treatment market in 2025. The regions covered in the neglected tropical disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neglected tropical disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the neglected tropical disease treatment market by increasing costs of imported active pharmaceutical ingredients, finished dosage forms, diagnostic supplies, and medical logistics equipment. Low- and middle-income regions in Africa, Asia-Pacific, and Latin America are most affected due to dependence on imported medicines and donor-funded supply chains. These tariffs are straining procurement budgets and distribution efficiency. However, they are also encouraging regional drug manufacturing, local formulation initiatives, and stronger domestic pharmaceutical capacity building.

The neglected tropical disease treatment market research report is one of a series of new reports that provides neglected tropical disease treatment market statistics, including neglected tropical disease treatment industry global market size, regional shares, competitors with a neglected tropical disease treatment market share, detailed neglected tropical disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neglected tropical disease treatment industry. This neglected tropical disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neglected tropical disease (NTD) treatment refers to medical interventions aimed at controlling, eliminating, or eradicating a group of infectious diseases that predominantly affect impoverished populations in tropical and subtropical regions. The primary goal of these treatments is to reduce disease burden, prevent disability, and improve the quality of life in affected communities.

The primary drug classes used in the treatment of neglected tropical diseases include anti-parasitic agents, antifungals, antibiotics, and others. Anti-parasitic agents are substances or treatments designed to prevent, kill, or eliminate parasitic organisms that infect humans, animals, or plants. These treatments target diseases such as leishmaniasis, schistosomiasis, lymphatic filariasis, Chagas disease, African trypanosomiasis, and others. Medications are administered via oral and parenteral routes and are distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies. They are used by a wide range of end users, including hospitals, specialty clinics, homecare settings, and others.

The neglected tropical disease treatment market consists of revenues earned by entities by providing services such as mass drug administration, disease surveillance, diagnostic testing, patient care and management, health education, and vector control programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The neglected tropical disease (NTD) treatment market also includes sales of diagnostic kits, vaccines, insecticides, and medical devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.